At least two types of cell death are known: physiological (apoptosis) and pathological (necrosis). Dysregulation of apoptosis plays an important role in the pathogenesis of many pathological conditions. Their analysis gives a key for the development of novel therapeutic approaches. In this review the recent advances and perspectives for clinical use of apoptosis-modulating monoclonal antibodies, low-molecular-weight proteins, peptides, small non-peptide molecules and drugs targeting apoptosis-associated genes are summarized. The rationale for clinical application of apoptomodulators with the aim of increasing efficacy of existing standard therapies are also discussed.
Ruemmele F.M., Beaulieu J.E, O'Connell J., Bennett M. W., Seidman E.G., Lentze M.J. (2002) Biochem. Biophys. Res. Commun. 290, 1308- 1314 . Scholar google search
Conway E.M., Pollefeyt S., Steiner- Mosonyi M., Luo W., Devriese A., Lupu E., Bono E., Leducq N., Dol E., Schaeffer P., Collen D., Herbert J.M. (2002) Gastroenterology. 123, 619- 631 . Scholar google search
Rasper D., Vaillancourt J., Hadano S., Houtzager V.M., Seiden I., Keen S.L., Tawa P., Xanthoudakis S., Nasir J., Martindale D., Koop B.E, Peterson E.P., Thornberry N.A., Huang J., MacPherson D.P., Black S.C., Hornung E., Lenardo M.J., Hoyden M.R., Roy S., Nicholson D.W. (1998) Cell Death Differ. 5, 271- 288. Scholar google search
